- Trials with a EudraCT protocol (7,245)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (10,738)
7,245 result(s) found.
Displaying page 1 of 363.
EudraCT Number: 2006-001095-21 | Sponsor Protocol Number: A5I16 | Start Date*: 2016-04-19 |
Sponsor Name:Sanofi Pasteur Inc. | ||
Full Title: Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed),... | ||
Medical condition: Pertussis, adsorbed diphtheria and tetanus toxoids, inactivated poliomyelitis and polysaccharide of H. influenza type b bound to tetanus toxoid | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-017346-32 | Sponsor Protocol Number: 201228 | Start Date*: 2010-03-15 | |||||||||||
Sponsor Name:Orchard Therapeutics (Europe) Ltd | |||||||||||||
Full Title: A PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME | |||||||||||||
Medical condition: Wiskott-Aldrich Syndrom | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016877-14 | Sponsor Protocol Number: H1N1-2009 | Start Date*: 2009-11-04 |
Sponsor Name:COPSAC | ||
Full Title: H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A-H1N1v Vaccination in Pregnant Women | ||
Medical condition: Protection against Influenza A H1N1v disease | ||
Disease: | ||
Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005629-65 | Sponsor Protocol Number: RG_12-269 | Start Date*: 2014-01-15 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study | |||||||||||||
Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002505-62 | Sponsor Protocol Number: STH16404 | Start Date*: 2013-11-14 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: SarCaBon: A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain | |||||||||||||
Medical condition: Cancer-induced bone pain | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002539-13 | Sponsor Protocol Number: CARE-ROP | Start Date*: 2014-04-01 | |||||||||||
Sponsor Name:University Medical Center Freiburg | |||||||||||||
Full Title: Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg... | |||||||||||||
Medical condition: retinopathy of prematurity | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003488-71 | Sponsor Protocol Number: OVG-2013/04 | Start Date*: 2013-12-12 |
Sponsor Name:University of Oxford | ||
Full Title: A pilot study of the impact of BCG administration on the immunogenicity of serogroup C meningococcal conjugate vaccine in healthy infants | ||
Medical condition: Vaccine responses | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020841-29 | Sponsor Protocol Number: ADAPT | Start Date*: 2011-07-07 | ||||||||||||||||
Sponsor Name:King`s College London [...] | ||||||||||||||||||
Full Title: The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema | ||||||||||||||||||
Medical condition: Severe eczema in children | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001109-22 | Sponsor Protocol Number: PBGM01-001 | Start Date*: Information not available in EudraCT |
Sponsor Name:Passage Bio, Inc. | ||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Su... | ||
Medical condition: GM1 gangliosidosis (GM1) is an autosomal recessive disorder that results from mutations in the human galactosidase beta 1 gene (GLB1), which encodes beta-galactosidase (β-gal). | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004898-32 | Sponsor Protocol Number: SAM103848 | Start Date*: 2016-12-08 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd. | ||
Full Title: Pediatric Asthma Clinical Effectiveness study (PEACE). A Randomized, Double-Blind, Double Dummy, Parallel Group comparative clinical study of Salmeterol/Fluticasone propionate Inhalation Powder (50... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000801-19 | Sponsor Protocol Number: MBMET_MEYER2017 | Start Date*: 2017-11-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER | |||||||||||||
Full Title: An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medullobla... | |||||||||||||
Medical condition: Metastatic medulloblastoma and other embryonal tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004053-76 | Sponsor Protocol Number: NL73102.018.20 | Start Date*: 2020-12-10 |
Sponsor Name:Amsterdam UMC [...] | ||
Full Title: Effectiveness of methylphenidate in children and adults with Smith Magenis syndrome and attention-deficit/hyperactivity disorder: An N-of-1 series | ||
Medical condition: Smith Magenis syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001133-40 | Sponsor Protocol Number: AT1001-025 | Start Date*: 2020-01-06 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Fabry Subjects with Amenable GLA Variants and Severe Renal Impairment | |||||||||||||
Medical condition: Fabry Subjects with Amenable GLA Variants and Severe Renal Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002109-20 | Sponsor Protocol Number: AAV2-hRPE65v2-301 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Spark Therapeutics, Inc. | |||||||||||||
Full Title: A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-h... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004900-44 | Sponsor Protocol Number: SF114570 | Start Date*: 2016-12-21 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl peroxide/Clindamycin gel and Tazarotene cream when used in combination in the Treat... | ||
Medical condition: Acne Vulgaris | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000263-32 | Sponsor Protocol Number: V260-028 | Start Date*: 2017-03-07 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Rotavirus Reassortant Vaccine in Chinese Healthy Adults, Children and Infants | |||||||||||||
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002849-30 | Sponsor Protocol Number: CCTL019B2101J/CHP-959 | Start Date*: 2017-11-16 | |||||||||||||||||||||
Sponsor Name:University of Pennsylvania | |||||||||||||||||||||||
Full Title: A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leuk... | |||||||||||||||||||||||
Medical condition: Chemotherapy resistant or refractory CD19+ B-cell Leukemia and Lymphoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-005111-40 | Sponsor Protocol Number: CN138-178 | Start Date*: 2017-04-07 |
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | ||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Flexible- Dosed Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder | ||
Medical condition: Autistic Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000611-17 | Sponsor Protocol Number: LTS12745 | Start Date*: 2017-08-28 | |||||||||||
Sponsor Name:Alfresa Pharma Corporation and Sanofi KK | |||||||||||||
Full Title: A Long term study of M071754 - A open-label study in patients with infantile spasms. | |||||||||||||
Medical condition: Patients diagnosed with infantile spasms | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000608-14 | Sponsor Protocol Number: 1.0/170119 | Start Date*: Information not available in EudraCT |
Sponsor Name:Tartu University Hospital | ||
Full Title: Prospective validation of individualized Bayesian dose optimization tool DosOpt for Vancomycin treatment in neonates. | ||
Medical condition: In neonatal population wide inter-and intra-individual variability of pharmacokinetics makes extremely difficult to ensure optimal exposure of vancomycin with standard regimens. On average >50% of ... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: EE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
